Business Context and Reporting Period
Company: Establishment Labs Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 15, 2025
Event: Regulation FD Disclosure regarding updated financial guidance presented at the J.P. Morgan Healthcare Conference.
Key Financial Metrics
The filing does not provide historical revenue, profit, cash flow, margins, debt, or liquidity figures for prior periods. It contains only forward-looking guidance for future periods.
Material Changes and Guidance
2025 Revenue Guidance
- Total Revenue: $205 million to $210 million.
- International Sales: $170 million to $175 million.
- United States Sales: $35 million.
Profitability and Cash Flow Outlook
- 2025 Adjusted EBITDA: Expected to be positive.
- 2026 Cash Flow: Expected to be positive.
Management Commentary and Risks
Management emphasizes that the provided estimates are forward-looking statements and should not be viewed as a substitute for full interim or annual financial statements prepared in accordance with U.S. GAAP. The preliminary financial data has not been audited, reviewed, compiled, or subjected to any procedures by Marcum LLP, the company's independent registered public accounting firm. Consequently, no assurance is expressed regarding the accuracy of this data.
Investor Verification Checklist
- Verify the specific assumptions underlying the $205 million to $210 million revenue range.
- Confirm the definition of "Adjusted EBITDA" used by management to ensure comparability with prior periods.
- Review upcoming audited financial statements to validate the preliminary guidance provided in this 8-K.
- Monitor the breakdown of international versus U.S. sales performance against the $170 million and $35 million targets respectively.